Molecular Templates

moleculartemplates.com

Molecular Templates (MTEM) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary Engineered Toxin Body (ETB) platform. MTEM’s first immunotoxin, MT-3724, is in clinical development for non-Hodgkin’s lymphoma. Pipeline products for additional oncology targets are being advanced toward clinical development. For more information, please visit MTEM’s website at www.mtem.com.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

VIRIOS THERAPEUTICS TO PRESENT AT THE VIRTUAL H.C. WAINWRIGHT BIOCONNECT CONFERENCE

Virios Therapeutics, Inc. | January 05, 2022

news image

Virios Therapeutics, Inc. a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference, which is taking place virtually January 10 - 13, 2022. The presentation will focus on the role of activated viruses triggering a wide range of conditions, includi...

Read More

Diagnostics

CANCER CELL PAPER IDENTIFIES "AVIDITY ENHANCEMENT" AS NEW STRATEGY FOR IMPROVING CAR T THERAPY FOR ACUTE MYELOID LEUKEMIA

LUMICKS | May 26, 2022

news image

LUMICKS, a leading life science tools company that develops instruments for dynamic single-molecule and cell avidity analysis, today announced the publication in Cancer Cell of preclinical research identifying "Avidity Enhancement" as a new strategy to improve therapeutic outcome of Chimeric Antigen Receptor (CAR) T cell immunotherapy in Acute Myeloid Leukemia (AML). AML poses significant clinical challenges due to its resistance to therapies and its bleak prognosi...

Read More

Industrial Impact

SARTORIUS STEDIM BIOTECH COMPLETES ACQUISITION OF NOVASEP'S CHROMATOGRAPHY DIVISION

Sartorius Stedim Biotech S.A. | February 08, 2022

news image

Sartorius Stedim Biotech, a leading partner of the biopharma industry, announced today that it closed the acquisition of the Novasep chromatography division as of February 7, 2022, following approval by the U.S. Federal Trade Commission. The transaction had already been agreed upon at the beginning of 2021. The business acquired generated sales of around 40 million euros in 2020 at a double-digit profit margin; final figures for 2021 are not yet available. The majority of the approximately 100 e...

Read More

Cell and Gene Therapy

TUMORGEN AND PHENOVISTA CAPTURE THE SEEDS THAT DRIVE CANCER METASTASIS

TumorGen Inc. and PhenoVista Biosciences LLC | September 09, 2022

news image

TumorGen Inc., and PhenoVista Biosciences LLC have successfully isolated and characterized metastatic cancer cell clusters from the blood of lung cancer patients’, validating TumorGen’s novel MCCC capture technology. This achievement is a critical milestone in developing anti-metastatic drugs, called “cluster busters,” which will target these cells and prevent cancer metastasis. “Anti-metastatic therapies that can stop tumors fro...

Read More
news image

Research

VIRIOS THERAPEUTICS TO PRESENT AT THE VIRTUAL H.C. WAINWRIGHT BIOCONNECT CONFERENCE

Virios Therapeutics, Inc. | January 05, 2022

Virios Therapeutics, Inc. a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference, which is taking place virtually January 10 - 13, 2022. The presentation will focus on the role of activated viruses triggering a wide range of conditions, includi...

Read More
news image

Diagnostics

CANCER CELL PAPER IDENTIFIES "AVIDITY ENHANCEMENT" AS NEW STRATEGY FOR IMPROVING CAR T THERAPY FOR ACUTE MYELOID LEUKEMIA

LUMICKS | May 26, 2022

LUMICKS, a leading life science tools company that develops instruments for dynamic single-molecule and cell avidity analysis, today announced the publication in Cancer Cell of preclinical research identifying "Avidity Enhancement" as a new strategy to improve therapeutic outcome of Chimeric Antigen Receptor (CAR) T cell immunotherapy in Acute Myeloid Leukemia (AML). AML poses significant clinical challenges due to its resistance to therapies and its bleak prognosi...

Read More
news image

Industrial Impact

SARTORIUS STEDIM BIOTECH COMPLETES ACQUISITION OF NOVASEP'S CHROMATOGRAPHY DIVISION

Sartorius Stedim Biotech S.A. | February 08, 2022

Sartorius Stedim Biotech, a leading partner of the biopharma industry, announced today that it closed the acquisition of the Novasep chromatography division as of February 7, 2022, following approval by the U.S. Federal Trade Commission. The transaction had already been agreed upon at the beginning of 2021. The business acquired generated sales of around 40 million euros in 2020 at a double-digit profit margin; final figures for 2021 are not yet available. The majority of the approximately 100 e...

Read More
news image

Cell and Gene Therapy

TUMORGEN AND PHENOVISTA CAPTURE THE SEEDS THAT DRIVE CANCER METASTASIS

TumorGen Inc. and PhenoVista Biosciences LLC | September 09, 2022

TumorGen Inc., and PhenoVista Biosciences LLC have successfully isolated and characterized metastatic cancer cell clusters from the blood of lung cancer patients’, validating TumorGen’s novel MCCC capture technology. This achievement is a critical milestone in developing anti-metastatic drugs, called “cluster busters,” which will target these cells and prevent cancer metastasis. “Anti-metastatic therapies that can stop tumors fro...

Read More